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Versican is a large chondroitin sulfate proteoglycan produced by human melanoma cell lines and malignant melanocytic lesions. In the
present work, we have analyzed the expression of versican spliced variants V0, V1, V2 and V3 in human melanoma cell lines at several
differentiation degrees. The isoform expression pattern depends on the degree of cell differentiation. Differentiated cell lines do not produce
any of the versican isoforms as analyzed by Western blot, Northern blot and RT-PCR. All cell lines with an early or intermediate degree of
differentiation (AX3, SK-mel-37, Rider, SK-mel-1.36-1–5 and SK-mel-3.44) expressed V0 and V1 transcripts, whereas V2 and V3
expression was shown only by the undifferentiated cell lines SK-mel-1.36-1–5 and Rider. Furthermore, we have analyzed the expression of
versican isoforms in SK-mel-3.44 and SK-mel-1.36-1–5 cells induced to differentiate by TPA treatment. The expression of the large V0, V1
and V2 isoforms practically disappears in differentiated cells, whereas V3 remains detectable by RT-PCR analysis.
D 2003 Elsevier B.V. All rights reserved.Keywords: Versican; Melanoma; Cell differentiation; Proteoglycan1. Introduction
Melanoma cells can vary widely in their degree of pigmen-
tation, cell morphology and growth rate, and these differences
can be observed in different metastases and even among the
various cellswithin individual lesions ofmelanomapatients. It
has been suggested that melanoma heterogeneity reflects a
corresponding diversity in the phenotype of normal cells
undergoingmelanocytedifferentiation [1,2].According to this
view, patterns of gene expression change as cells progress
through distinct stages in the melanocyte lineage.
The extracellular matrix (ECM) surrounding the cells is
an important element controlling cell behavior in aspects
such as cell proliferation, adhesion and migration. One of
the main ECM components are proteoglycans (PGs). Al-
tered PGs have been described in tumors and transformed
cells, and are believed to contribute to the abnormal assem-
bly of the ECM in those cells [3–6]. Tumor cell ECM is
usually abundant in hyaluronan, which forms a tridimen-0167-4889/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/S0167-4889(03)00104-6
$ Supported by grant 00/1016 from the Fondo de Investigaciones
Sanitarias (FIS) and 2001SGR00193 from the Generalitat de Catalunya. C.D.
and M.S. are supported by a fellowship from the Generalitat de Catalunya.
M.J.D. is supported by Ministerio de Educacio´n, Cultura y Deporte.
* Corresponding author. Tel.: +34-3-5811-042; fax: +34-3-5812-006.
E-mail address: anna.bassols@uab.es (A. Bassols).sional network with chondroitin sulfate proteoglycans from
the hyalectan family as well as with other molecules [7–9].
We have previously described the presence of versican, a
member of the hyalectan family in humanmelanoma cell lines
and malignant melanoma in vivo and related the role of
versican to the biological properties of melanoma cells [10].
In that work, we have shown that versican expression clearly
correlates with melanoma cell differentiation stage since only
cell lineswith an early and intermediate differentiation degree,
but not differentiated cells, produce versican.
Versican, as well as the other members of the hyalectan
family, displays three structural domains: the N-terminal
region (G1 domain) consists of an immunoglobulin-like
loop and two link protein-like tandem repeats and is
responsible for hyaluronate binding; the central domain
carries the glycosaminoglycan side chains and the C-termi-
nal globular region (G3 domain) consists of two EGF-like
elements, a C-type lectin domain and a CRP-like (sushi)
module; it may interact with simple carbohydrates and
glycosaminoglycans and probably with other proteins such
as tenascin-R [11,12]. The central versican domain consists
of two large subdomains, designated GAG-a and GAG-h,
which are encoded by two alternatively spliced exons. In
mammals, versican appears as four possible spliced variants:
V0 is the largest one and contains both GAG-a and GAG-h;
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GAG-a) and V3 (lacks any GAG subdomain).
In the present work, we have further analyzed the
expression of spliced versican isoforms in human melanoma
cell lines with different degrees of differentiation as well as
investigated the relationship between versican expression
and the melanoma cell differentiation process induced by
12-O-tetradecanoyl-phorbol-13-myristate acetate (TPA).Fig. 2. Detection of versican isoforms (V0, V1, V2 and V3) in human
melanoma cell lines using RT-PCR. RT-PCR was performed with total
RNA from U-251 astrocytoma and melanoma cell lines with an early (E),
intermediate (I) or late (L) differentiation degree as described in Materials
and methods. Glyceraldehyde-3-phosphate-dehydrogenase (GAPDH)
served as a positive control.2. Materials and methods
2.1. Cell culture
Human melanoma cell lines SK-mel-131 (cl 1.36-1–5),
SK-mel-131 (cl 3.44), SK-mel-23, SK-mel-37, Rider, AX3,
MeWo and DX2 originally derived from human melanomas
by Houghton et al. [2] were obtained from Dr. F.X. Real
(IMIM-IMAS, Barcelona, Spain). Cells were grown in a
humidified atmosphere at 37 jC with 5% CO2 in DMEM
medium supplemented with 10% fetal calf serum, 100 IU/ml
penicillin and 100 Ag/ml streptomycin (all from GibcoBRL/
Life Technologies, Paisley, Scotland). The medium was then
removed, a cocktail of protease inhibitors was added (10 mM
EDTA, 5 mM benzamidine (Sigma, St. Louis, MO) and 1
mM PMSF (Boehringer Mannheim, Mannheim, Germany))Fig. 1. Identification of versican isoforms and mel-CSPG in human
melanoma cell lines. Conditioned media from human melanoma cell lines
and U-251 astrocytoma cell line were treated with chondroitinase ABC and
analyzed by Western blot with: (A) the antibody raised against versican and
(B) the monoclonal antibody B5 raised against the melanoma-specific
proteoglycan mel-CSPG as described in Materials and methods. I,
intermediate differentiation degree; E, early differentiation degree; L, late
differentiation degree. The 240 and 250 kDa bands corresponding to distinct
glycosylated forms of mel-CSPG are shown.and analyzed by SDS-PAGE in a 6% polyacrylamide gel, as
described by Laemmli [13]. To assure that the conditioned
medium corresponding to the same number of cells was
used, duplicate wells were seeded and cells were counted in a
Neubauer chamber.
For differentiation studies, 2 104 cells were seeded in
6-well plates in complete medium. After 24 h, medium was
supplemented with 160 nM TPA (Sigma) dissolved in
DMSO (Sigma) [1]. Control cells were grown in DMEM
or DMEM supplemented with 0.0016% DMSO. Medium
was changed every 72 h and kept at  20 jC in the presence
of protease inhibitors.
2.2. Western blot analysis
Enzymatic digestions were performed at 37 jC for 16
h with chondroitinase ABC (Sigma) (50 mU/ml in 33 mM
sodium acetate, 33 mM Tris–HCl pH 8.0). The incubations
were terminated by boiling the samples for 5 min. Samples
were analyzed in a 6% polyacrylamide gel under reducing
conditions. After electrophoresis, proteins were transferred
onto Immobilon-P membranes (Millipore Corporation, Bed-
ford, MA). The blot was placed in a blocking solution
consisting of 5% skim milk in 0.05 M Tris Buffer, 0.15 M
NaCl (TBS)-0.05% Tween-20 (Serva, Heidelberg, Germany)
and incubated for 1 h at room temperature. The membranes
were incubated with the polyclonal antibody against versican
raised in our laboratory (1:1000) [10] or the monoclonal
antibody B5 raised against mel-CSPG (1:50) (kindly provid-
ed by Dr. F.X. Real, IMIM-IMAS, Barcelona) [14] in 5%
Fig. 4. Morphological changes in SK-mel-3.44 and SK-mel-1.36-1–5 human mel
cultures were treated with 160 nM TPA as described in Materials and methods. Cu
with an integrated camera system.
Fig. 3. Northern blot analysis of versican isoforms in total RNA from
human melanoma cell lines. Versican isoforms mRNA was specifically
detected with probes covering sequences coding for the hyaluronan-binding
region (HABR), the glycosaminoglycan attachment subdomain GAG-h or
the glycosaminoglycan attachment subdomain GAG-a.
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by chemiluminescence (ECL System, Amersham Pharmacia
Biotech, Buckinghamshire, England).
2.3. Immunocytochemistry
Cells were grown in cover slips, rinsed with PBS and fixed
with 3% paraformaldehyde-2% sacarose for 20 min at room
temperature. After rinsing with PBS, cells were permeabi-
lized with 0.1% Triton X-100 in PBS for 10 min and
nonspecific binding sites were blocked for 20 min with 1%
BSA/0.02% goat serum. Cells were then incubated for 3 h at
37 jC with the anti-versican antibody (1:1000), the B5
antibody against mel-CSPG (1:50) or with theM111 antibody
against gp110 (1:100) [1] (kindly provided by Dr. F.X. Real,
IMIM-IMAS, Barcelona). Subsequently, cells were washed
four times with PBS and incubated with the corresponding
secondary antibody labeled with FITC (versican, M111)
(Southern Biotechnology Association, Birmingham, AL) or
TRITC (B5) (Sigma). Nuclei were visualized by incubating
the cover slips with Hoetsch (0.1 mg/ml in PBS) for 3 min.
Cultures were studied with a Nikon Eclipse E800 epifluor-
escence microscope and photographed with an integrated
camera system.
2.4. RNA isolation, Northern blot hybridization and
RT-PCR
Total RNA was extracted with RNeasy isolation kit
(Qiagen, Hilden, Germany) from subconfluent cells. For
Northern blot experiments, 15 Ag of total RNA were sepa-
rated by 1% agarose-formaldehyde gel electrophoresis and
subsequently transferred onto Hybond-XL membranes
(Amersham Pharmacia Biotech). The following [alpha-32P]anoma cell lines after induction of differentiation with TPA treatment. Cell
ltures were viewed with a Leica Fluovert-Fu microscope and photographed
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binding region), Genomic PCR (GAG-a) and C4 (GAG-h) as
described by Dours-Zimmermann and Zimmermann [15].
For RT-PCR, 1 Ag of total RNAwas reverse transcribed in
a 20 Al reaction volume with the Expand Reverse Transcrip-
tase (Roche, Mannheim, Germany) as described in the
protocol provided by the supplier. Ten microliters of the
reaction mix were subsequently used for PCR. The primers
used for amplification of the specific splice variants of
versican were those described in Paulus et al. [16]. Thirty
cycles were performed, each cycle including 1min at 94 jC, 1
min at 55 jC for V0 and V1 or at 53 jC for V2 and V3
isoforms and 1min at 72 jC. The final extension step at 72 jC
was carried out for 10 min. MgCl2 concentration was 2 mM
for V1 and V2, and 2.5 mM for V0 and V3. The size of the
amplification products were 351 bp (V0), 386 bp (V1), 373
bp (V2) and 342 bp (V3). As positive control, we used RT-
PCR amplification of a 960-bp fragment of glyceraldehyde 3-Fig. 5. Changes in the expression of versican and differentiation markers during t
mel-3.44 (A) and SK-mel-1.36-1–5 (B) melanoma cells were grown in cover slips
methods. After 12 days of treatment, cells were fixed with paraformaldehyde. Aft
with the monoclonal antibody B5 against mel-CSPG, or with the monoclonal an
Cultures were viewed with a Nikon Eclipse E800 epifluorescence microscope anphosphate dehydrogenase (for GAPDHprimers, see Paulus et
al.; amplification conditions: 30 cycles including 1 min at 94
jC, 1 min at 55 jC and 1 min at 72 jC; 1.2 mMMgCl2). As a
control for DNA contamination of the RNA preparation, PCR
was performed without the initial reverse transcriptase step.
Amplification products were resolved on 2% agarose gels
stained with ethidium bromide. All the amplification frag-
ments were isolated and digested with an appropriate restric-
tion enzyme to confirm their identity (not shown).3. Results
3.1. Identification of versican and mel-CSPG in human
melanoma cell lines
Conditioned media from a number of human melanoma
cell lines subconfluent cultures were collected, treated withhe process of melanoma differentiation induced by TPA. Subconfluent SK-
and treated with TPA to induce differentiation as described in Materials and
er permeabilization, cells were incubated with the anti-versican antibody, or
tibody M111 against gp110. Nuclei were visualized with Hoestch (insert).
d photographed with an integrated camera system.
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and analyzed by Western blot using a polyclonal antibody
against versican raised in our laboratory [10] and with the
monoclonal antibody B5 raised against the melanoma-spe-
cific proteoglycan mel-CSPG [14]. The results presented in
Fig. 1A show that cells with an intermediate differentiation
degree (SK-mel-3.44) and all the undifferentiated cell lines
(SK-mel-1.36-1–5, SK-mel-37, Rider and AX3) expressed
the high molecular weight versican isoforms V0 and V1 in
variable amounts, whereas the differentiated cell lines SK-
mel-23, MeWo and DX2 cell lines did not express any
versican isoform. Mel-CSPG, considered an undifferentiated
melanoma marker, was also expressed only in undifferenti-
ated cell lines and absent from the differentiated ones, except
the DX2 cells (Fig. 1B). The human astrocytoma cell line
U251 was used as a control.
3.2. Detection of versican isoforms in human melanoma cell
lines
Only the major V0 and V1 versican isoforms were
visualized by Western blot. So, we used RT-PCR and
Northern blot assays to analyze the production of V2 and
V3 isoforms in our panel of melanoma cell lines. The human
astrocytoma cell line U251 was used as a control since it has
been described that astrocytomas express all four versican
splice variants [16].
RT-PCR results are illustrated in Fig. 2. None of the
differentiated melanoma cell lines (SK-mel-23, MeWo and
DX-2) expressed any of the four isoforms. All cell lines with
an early or intermediate differentiation degree (SK-mel-1.36-
1–5, SK-mel-37, Rider and SK-mel-3.44) expressed V0 and
V1 transcripts. V2 and V3 expression was only shown by the
undifferentiated cell lines SK-mel-1.36-1–5, SK-mel-37 and
Rider. However, no quantitative assertion could be madeFig. 6. Versican and mel-CSPG expression during the process of melanoma cell d
SK-mel-1.36-1–5 (B) melanoma cells were treated with 160 nM TPA to induce
times, conditioned media were collected, digested with chondroitinase ABC and a
antibody B5 against mel-CSPG. The 240 kDa and 250 kDa bands correspondingbased on these experiments. Therefore, we prepared North-
ern blots that yielded similar results (Fig. 3). Transcripts for
V0 and V1 were visualized in all the undifferentiated and
intermediate cell lines using a probe for GAG-h, as a double
band around 13 kb and a duplex at 10 kb as has been
described for U251 astrocytoma cells [15]. V2 was observed
only in the undifferentiated cell lines SK-mel-1.36-1–5 and
Rider by using a probe for the GAG-a subdomain requiring a
six-times longer exposure period. With a probe prepared for
the HABR region common to all the four isoforms, we could
only detect two bands corresponding to V0 and V1, indicat-
ing that V2 transcript expression is lower. V3 transcript
remained below the Northern blot detection limit. Differen-
tiated cell lines did not show any versican isoform. We also
checked whether the isoform pattern was altered by the
degree of confluence, but this condition did not change the
versican isoform expression (not shown).
3.3. Expression of versican along the differentiation process
of melanoma cells
The abovementioned results show a close relationship
between versican expression and cell differentiation. There-
fore, we induced the differentiation process in vitro by
treating cultures from SK-mel-1.36-1–5 and SK-mel-3.44
with the differentiation agent TPA [1]. Morphological
changes induced by TPA are shown in Fig. 4. This process
has been fully characterized by determining the expression of
a number of differentiation antigens. Mel-CSPG is one of
these antigens since it is expressed only by undifferentiated
cells and disappears in TPA-differentiated melanoma cells.
Other antigens are induced by the differentiation process, as
gp110, gp180 or the melanosome antigen, and are considered
late markers. They are recognized by the monoclonal anti-
bodies M111, C350 and CF21, respectively [1]. Therefore,ifferentiation analyzed by Western blot. Subconfluent SK-mel-3.44 (A) and
cell differentiation as described in Materials and methods. At the indicated
nalyzed by Western blot with the anti-versican antibody or the monoclonal
to distinct glycosylated forms of mel-CSPG are shown.
Fig. 7. Expression of versican isoforms during the process of melanoma cell
differentiation analyzed by RT-PCR. Subconfluent SK-mel-3.44 (A) and
SK-mel-1.36-1–5 (B) melanoma cells were treated with 160 nM TPA to
induce cell differentiation as described in Materials and methods. Before
treatment and after 15 days in the presence of TPA, total RNAwas extracted
and RT-PCR analysis was performed as described in Materials and methods.
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follow the differentiation process.
Versican disappears 15 days after induction of SK-mel-
1.36-1–5 and SK-mel-3.44 cells differentiation, similarly to
mel-CSPG expression, as shown by immunocytochemistry
experiments, whereas the gp110 antigen recognized by
M111 is induced after TPA treatment (Fig. 5). C350 and
CF21 showed a pattern similar to M111 (not shown). A
more detailed analysis has been performed by Western blot
from cell-conditioned media collected at several days along
the differentiation process (Fig. 6). Mel-CSPG rapidly
disappears in SK-mel-3.44 cells whereas it decreases at a
slower rate in SK-mel-1.36-1–5 cells. Versican expression
does not follow the same pattern since its disappearance rate
is slower in SK-mel-3.44 cells. Both V0 and V1 isoforms
decrease in a parallel way.
We subsequently looked at the four versican isoforms
expression by RT-PCR in SK-mel-1.36-1–5 and SK-mel-
3.44 cells before and after TPA-induced differentiation (Fig.
7). Control SK-mel-3.44 cells expressed V0, V1 and V3
isoforms, whereas we could detect only V0 in induced cells.
In SK-mel-1.36-1–5 cells, we could detect V0 and V3 after
differentiation although V1 and V2 were undetectable.4. Discussion
It is widely accepted that during tumor progression, in
which cells acquire their enhanced ability to proliferate and
migrate, cells regress to an undifferentiated phenotype. In
melanoma, this process is characterized by the expression orrepression at different periods of a wide range of molecules
and, in consequence, the panel of antigens expressed by a
selected melanoma or by melanoma cell lines defines their
differentiation degree [2]. It has been proposed that the three
differentiation degrees (early, intermediate and late) of
melanoma tumor cell lines would correspond to the normal
melanocyte features at the early, intermediate or mature
phases in melanocyte differentiation, as they express a
similar set of differentiation antigens.
In a previous work, we have identified the expression of
a new malignant melanoma marker, the extracellular pro-
teoglycan versican. Versican is expressed in a high percent-
age of malignant melanomas [10], whereas the expression
is much lower in dysplastic nevi and null in benign
melanocytic nevi [17]. This finding supports the existence
of a melanoma progression pathway, where the dysplastic
nevus represents a precursor of malignant melanoma [18].
In the present work, we have analyzed the expression of
different versican isoforms in melanoma cell lines, to study
the relationship between the expression of this proteoglycan
and the degree of cell differentiation in vitro, which would
correspond to different stages in melanoma development.
Our results show that, extending our previous findings, SK-
mel-23, MeWo and DX2 differentiated melanoma cell lines
do not produce any versican isoform. The early-differenti-
ated cells (SK-mel-1.36-1–5, SK-mel-37 and Rider) pro-
duce all versican isoforms, as detected by RT-PCR,
although quantitative differences were detected when using
Northern blot analysis. In this case, V0 and V1 were the
most abundant isoforms in undifferentiated cell lines. V0
isoform, which has been suggested as the prevalent one
during early embryonic development [19–21] is present
here. The V2 isoform, which is supposed to be abundant in
neural tissues [22], is also present, perhaps as a conse-
quence of their neuroectodermal origin. Nevertheless, the
level of V2 should be much lower than V0/V1 isoforms,
since the time of exposure for the Northern blot had to be
six times longer to get similar band intensity. Furthermore,
we could not detect any band corresponding to V2 in
Western blot, although our antibody is able to recognize a
band similar to V2 in bovine brain extracts (not shown).
The short V3 isoform is detected by RT-PCR, although we
could not detect it by Northern blot. SK-mel-3.44 cells, that
have an intermediate degree of differentiation, show the
presence of V0, V1 and V3 by Northern blot and RT-PCR.
In consequence, we propose that the loss of the differenti-
ated state in melanoma cells is accompanied by the expres-
sion of versican isoforms. From the differences between
cell lines in an intermediate or early differentiation degree,
we suggest that V0, V1 and V3 are expressed first, and
finally V2.
These differences may have functional consequences:
although all isoforms share the same N- and C-terminal
domains and should be able to establish the same interactions
with other molecules, the central domain is differently
spliced. Therefore, the number of glycosaminoglycan chains
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amount of GAG chains and therefore is the most negatively
charged, V1 and V2 have a minor amount of chains and a
minor charge, and V3 has no GAG chains. The existing
distance between the N- and C-terminal domains should also
be different. These differences should affect the ability of
versican to interact with its ligands and, most probably, its
physiological properties. Although there are no definitive
studies on the possible differential biological role of the
isoforms, it has been suggested that GAG domain size could
modulate versican axonal growth inhibitory capacity in the
nervous system [23].
To ascertain if this process is reversible, we assessed
whether versican expression is down regulated in undiffer-
entiated SK-mel-3.44 and SK-mel-1.36-1–5 melanoma cells
grown in a differentiation-promoting conditions, i.e., in
presence of TPA. The differentiation process has been fully
characterized in these specific cell lines [1], and it is widely
accepted that TPA suppresses the growth of melanoma cells,
and that this process is frequently accompanied by terminal
differentiation [24–26]. Our results demonstrate that versi-
can expression decreases in these conditions, linking differ-
entiation state and versican expression. In both cases, we
used mel-CSPG expression, a well-known melanoma-asso-
ciated antigen present in undifferentiated cell lines and
absent from differentiated ones, and gp110, a late differen-
tiation antigen for melanoma, as markers to follow the
process. The expression of V0 and V1, the two isoforms
detected by Western blot, decreases at a parallel rate,
although V0 remains detectable by RT-PCR, as well as V3
in SK-mel-1.36–5 cells. There are other indications in the
literature that relate versican expression and cell prolifera-
tion/differentiation, although there have been no studies on
the presence of particular isoforms. Thus, versican is down-
regulated in culture conditions promoting keratinocyte dif-
ferentiation but is up-regulated in keratinocytes grown in
proliferation-promoting conditions [27].
Although the molecular mechanism for versican regula-
tion during cell differentiation is not known, it is clearly
established that versican isoform expression and splicing are
developmentally regulated, especially in the nervous system
and during neural crest migration and differentiation [20,
21,28]. Recently, it has been also described that the versican
gene may be a target for Pax3, a transcription factor involved
in neural crest cell development. Pax3 is expressed in a
spatiotemporally restricted manner during embryogenesis
[29], and it has been suggested that it regulates the expres-
sion of genes involved in cell adhesion and mobility,
influencing in this manner the migration of neural crest cells,
which will give origin to melanocytes [30]. Pax3 is overex-
pressed in malignant melanoma and not in benign nevi [31].
It has been recently described that versican V2 isoform is up-
regulated in Pax3-transfected cells, although no consensus
sequence for Pax3 is found in the versican promoter [32].
Nevertheless, the versican promoter includes several other
regulatory sites (AP2, SP1, CTF/CBF, CBP, CREB and C/EBP) [33], and some of these transcription factors are
developmentally regulated [34,35].
Finally, it is interesting to note that all the undifferentiated
cell lines produce the short V3 isoform. This isoform lacks
GAG chains, and it has been described that it may have
opposite functional roles to the large isoforms by exerting a
functional competition with them [36]. The expression of V3
has been reported in several cells and tissues as adult brain,
fetal liver [37,38], smooth muscle cells [39], and others [19].
In endothelial cells, V3 is specifically expressed after acti-
vation with cytokines as TNF-a or VEGF, being therefore
associated with neoangiogenesis and wound healing pro-
cesses [19]. In our case, V3 remains detectable after the
induction of melanoma cell differentiation, raising the pos-
sibility of a specific role for this isoform.
In conclusion, we propose that versican production by
melanoma cells is a sign of regression to an undifferentiated
state during tumor progression, and that there is a different
time appearance pattern for versican isoforms.Acknowledgements
We thank Dr. F.X. Real (IMIM-IMAS, Barcelona, Spain)
for providing the cell lines and the monoclonal antibodies
used in this work, Dr. D.R. Zimmermann (University of
Zu¨rich, Switzerland) for the probes against HABR, GAG-a
and GAG-h, and Ms. Anna Vilalta for her excellent
technical assistance.References
[1] A.N. Houghton, F.X. Real, L.J. Davis, C. Cordon-Cardo, L.J. Old,
Phenotypic heterogeneity of melanoma. Relation to the differentiation
program of melanoma cells, J. Exp. Med. 165 (1987) 812–829.
[2] A.N. Houghton, M. Eisinger, A.P. Albino, J.G. Cairncross, L.J. Old,
Surface antigens of melanocytes and melanomas. Markers of mela-
nocyte differentiation and melanoma subsets, J. Exp. Med. 156 (1982)
1755–1766.
[3] M. Sobue, J. Takeuchi, K. Yoshida, S. Akao, T. Fukatsu, T. Nagasaka,
N. Nakashima, Isolation and characterization of proteoglycans from
human nonepithelial tumors, Cancer Res. 47 (1987) 160–168.
[4] M. Alini, G.A. Losa, Partial characterization of proteoglycans isolated
from neoplastic and nonneoplastic human breast tissues, Cancer Res.
51 (1991) 1443–1447.
[5] Y. Nara, Y. Kato, Y. Torii, Y. Tsuji, S. Nakagaki, S. Goto, H. Isobe, N.
Nakashima, J. Takeuchi, Immunohistochemical localization of extra
cellular matrix components in human breast tumours with special
reference to PG-M/versican, Histochem. J. 29 (1997) 21–30.
[6] C. Ricciardelli, K. Mayne, P.J. Sykes, W.A. Raymond, K. McCaul,
V.R. Marshall, W.D. Tilley, J.M. Skinner, D.J. Horsfall, Elevated
stromal chondroitin sulfate glycosaminoglycan predicts progression
in early-stage prostate cancer, Clin. Cancer Res. 3 (1997) 983–992.
[7] E.A. Turley, M. Tretiak, Glycosaminoglycan production by murine
melanoma variants in vivo and in vitro, Cancer Res. 45 (1985)
5098–5105.
[8] W. Knudson, Tumor-associated hyaluronan: providing an extracel-
lular matrix that facilitates invasion, Am. J. Pathol. 148 (1996)
1721–1726.
C. Domenzain et al. / Biochimica et Biophysica Acta 1642 (2003) 107–114114[9] B.P. Toole, T.N. Wight, M.I. Tammi, Hyaluronan–cell interactions in
cancer and vascular disease, J. Biol. Chem. 277 (2002) 4593–4596.
[10] M. Touab, J. Villena, C. Barranco, M. Arumi-Uria, A. Bassols, Ver-
sican is differentially expressed in human melanoma and may play a
role in tumor development, Am. J. Pathol. 160 (2002) 549–557.
[11] R.V. Iozzo, Matrix proteoglycans: from molecular design to cellular
function, Ann. Rev. Biochem. 67 (1998) 609–652.
[12] D.R. Zimmermann, Versican, in: R.V. Iozzo (Ed.), Proteoglycans:
Structure, Biology and Molecular Interactions, Marcel Dekker, New
York, 2000, pp. 327–341.
[13] U.K. Laemmli, Cleavage of structural proteins during the assembly of
the head of bacteriophage T4, Nature 227 (1970) 680–685.
[14] A. Heredia, J. Villena, M. Romaris, A. Molist, A. Bassols, Trans-
forming growth factor beta 1 increases the synthesis and shedding
of the melanoma-specific proteoglycan in human melanoma cells,
Arch. Biochem. Biophys. 333 (1996) 198–206.
[15] M.T. Dours-Zimmermann, D.R. Zimmermann, A novel glycosamino-
glycan attachment domain identified in two alternative splice variants
of human versican, J. Biol. Chem. 269 (1994) 32992–32998.
[16] W. Paulus, I. Baur, M.T. Dours-Zimmermann, D.R. Zimmermann,
Differential expression of versican isoforms in brain tumors, J. Neuro-
pathol. Exp. Neurol. 55 (1996) 528–533.
[17] M. Touab, M. Arumi-Uria, C. Barranco, A. Bassols, Expression of the
proteoglycans versican and mel-CSPG in dysplastic nevi, Am. J. Clin.
Pathol. 119 (2003) 587–593.
[18] F. Meier, K. Satyamoorthy, M. Nesbit, M.Y. Hsu, B. Schittek, C.
Garbe, M. Herlyn, Molecular events in melanoma development and
progression, Front. Biosci. 3 (1998) D1005–D1010.
[19] S. Cattaruzza, M. Schiappacassi, A. Ljungberg-Rose, P. Spessotto,
D. Perissinotto, M. Morgelin, M.T. Mucignat, A. Colombatti, R.
Perris, Distribution of PG-M/versican variants in human tissues
and de novo expression of isoform V3 upon endothelial cell activa-
tion, migration, and neoangiogenesis in vitro, J. Biol. Chem. 277
(2002) 47626–47635.
[20] M. Stigson, J. Lofberg, L. Kjellen, PG-M/versican-like proteoglycans
are components of large disulfide-stabilized complexes in the axolotl
embryo, J. Biol. Chem. 272 (1997) 3246–3253.
[21] D. Perissinotto, P. Iacopetti, I. Bellina, R. Doliana, A. Colombatti, Z.
Pettway, M. Bronner-Fraser, T. Shinomura, K. Kimata, M. Morgelin,
J. Lofberg, R. Perris, Avian neural crest cell migration is diversely
regulated by the two major hyaluronan-binding proteoglycans PG-
M/versican and aggrecan, Development 127 (2000) 2823–2842.
[22] M. Schmalfeldt, C.E. Bandtlow, M.T. Dours-Zimmermann, K.H.
Winterhalter, D.R. Zimmermann, Brain derived versican V2 is a po-
tent inhibitor of axonal growth, J. Cell. Sci. 113 (2000) 807–816.
[23] M. Schmalfeldt, M.T. Dours-Zimmermann, K.H. Winterhalter, D.R.
Zimmermann, Versican V2 is a major extracellular matrix component
of the mature bovine brain, J. Biol. Chem. 273 (1998) 15758–15764.
[24] H. Li, N.U. Ahmed, M.H. Fenner, M. Ueda, K.J. Isselbacher, T.
Shioda, Regulation of expression of MSG1 melanocyte-specific nu-clear protein in human melanocytes and melanoma cells, Exp. Cell
Res. 242 (1998) 478–486.
[25] D.C. Bennett, Genetics, development, and malignancy of melano-
cytes, Int. Rev. Cyt. 146 (1993) 191–260.
[26] S. Prince, T. Wiggins, P.A. Hulley, S.H. Kidson, Stimulation of mel-
anogenesis by tetradecanoylphorbol 13-acetate (TPA) in mouse mel-
anocytes and neural crest cells, Pigment Cell. Res. 16 (2003) 26–34.
[27] D.R. Zimmermann, M.T. Dours-Zimmermann, M. Schubert, L.
Bruckner-Tuderman, Versican is expressed in the proliferating zone
in the epidermis and in association with the elastic network of the
dermis, J. Cell Biol. 124 (1994) 817–825.
[28] P. Milev, P. Maurel, A. Chiba, M. Mevissen, S. Popp, Y. Yamaguchi,
R.K. Margolis, R.U. Margolis, Differential regulation of expression of
hyaluronan-binding proteoglycans in developing brain: aggrecan, ver-
sican, neurocan, and brevican, Biochem. Biophys. Res. Commun. 247
(1998) 207–212.
[29] M.D. Goulding, G. Chalepakis, U. Deutsch, J.R. Erselius, P. Gruss,
Pax-3, a novel murine DNA binding protein expressed during early
neurogenesis, EMBO J. 10 (1991) 1135–1147.
[30] P. Pla, R. Moore, O.G. Morali, S. Grille, S. Martinozzi, V. Delmas, L.
Larue, Cadherins in neural crest cell development and transformation,
J. Cell. Physiol. 189 (2001) 121–132.
[31] F.A. Scholl, J. Kamarashev, O.V. Murmann, R. Geertsen, R. Dummer,
B.W. Schafer, PAX3 is expressed in human melanomas and contrib-
utes to tumor cell survival, Cancer Res. 61 (2001) 823–826.
[32] C.S. Mayanil, D. George, L. Freilich, E.J. Miljan, B. Mania-Farnell,
D.G. McLone, E.G. Bremer, Microarray analysis detects novel Pax3
downstream target genes, J. Biol. Chem. 276 (2001) 49299–49309.
[33] M.F. Naso, D.R. Zimmermann, R.V. Iozzo, Characterization of the
complete genomic structure of the human versican gene and functional
analysis of its promoter, J. Biol. Chem. 169 (1994) 32990–33008.
[34] P.J. Mitchell, P.M. Timmons, J.M. Hebert, P.W. Rigby, R. Tjian, Tran-
scription factor AP-2 is expressed in neural crest cell lineages during
mouse embryogenesis, Genes Dev. 5 (1991) 105–119.
[35] J.D. Saffer, S.P. Jackson, M.B. Annarella, Developmental expression
of Sp1 in the mouse, Mol. Cell. Biol. 11 (1991) 2189–2199.
[36] J.M. Lemire, M.J. Merrilees, K.R. Braun, T.N. Wight, Overexpression
of the V3 variant of versican alters arterial smooth muscle cell adhe-
sion, migration and proliferation in vitro, J. Cell. Physiol. 190 (2002)
38–45.
[37] K. Ito, T. Shinomura, M. Zako, M. Ujita, K. Kimata, Multiple forms
of mouse PG-M, a large chondroitin sulfate proteoglycan generated
by alternative splicing, J. Biol. Chem. 270 (1995) 958–965.
[38] M. Zako, T. Shinomura, M. Ujita, K. Ito, K. Kimata, Expression of
PG-M(V3), an alternatively spliced form of PG-M without a chon-
droitin sulfate attachment in region in mouse and human tissues,
J. Biol. Chem. 270 (1995) 3914–3918.
[39] J.M. Lemire, K.R. Braun, P. Maurel, E.D. Kaplan, S.M. Schwartz,
T.N. Wight, Versican/PG-M isoforms in vascular smooth muscle cells,
Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1630–1639.
